

Tuesday, 29 June 2021

15:40-16:00 Opening

- ♦ Welcome
- ♦ Introduction EBMT and COVID19 pandemic

Rafael de la Cámara (Spain)
Nicolaus Kröger (Germany)

16:00-17:35 The virus

- ♦ Mutations, variants and strains. *What do they mean? How do they emerge? What is the situation of the new strains? What implications they have?*
- ♦ Diagnostic Toolbox for SARS-CoV-2: What Works When and Why?
- ♦ Prolonged PCR positivity in HSCT and oncohematologic patients. *How frequent is it? What means?*
- ♦ Update on SARS-COV-2 transmission mechanisms
- ♦ Live Q&A

Chair: D. Navarro

Fernando González Candelas (Spain)

Hans Hirsch (Switzerland)

Fausto Baldanti (Italy)

Lidia Morawska (Australia)

17:35-17:45 Break

17:45-18:15 Quality in HSCT

- ♦ Maintaining quality standards during the COVID-19 pandemic
- ♦ Live Q&A

Chairs: N. Worel & J. Snowden

John Snowden (UK) & **Sarah Holtby** (UK)

18:15-18:25 Break

18:25-19:50 Donors' standards

- ♦ Do we have to test donors for SARS-CoV-2? *When and how?*
- ♦ Impact of cryopreservation in HSCT outcome
- ♦ Related donors
- ♦ Unrelated Donors
- ♦ Live Q&A

Chairs: N. Worel & J. Snowden

Rafael de la Cámara (Spain)
Boris Calmels (France)
Nina Worel (Austria)
Hung Yang (Australia)

Wednesday, 30 June 2021

15:45-17:00 Clinical Impact and management in HSCT patient 1 Chairs: P. Ljungman & M. Mikulska

Activity impact and clinical outcome

- ◆ EBMT experience
- ◆ USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center
- ◆ Asian Pacific BM Society experience (APBMT)
- ◆ Live Q&A

Per Ljungman (Sweden)
Genovefa Papanicolau (USA)

William YK Hwang (Singapore)

17:00-17:10 Break

17:10-18:00 Clinical Impact and management in HSCT patient 2 Chairs: P. Ljungman & M. Mikulska

- ◆ Other/organ complications
- ◆ Measures to limit SARS-COV-2 nosocomial outbreaks in transplant units
- ◆ Live Q&A

Akshay Sharma (USA)
Roy Chemaly (USA)

18:00-18:15 Break

18:15-19:30 Clinical Impact and management in HSCT patient 3 Chairs: J. Styczynski & R. de la Cámara

- ◆ COVID -19 in HSCT paediatric patients. *It is really a low frequency and benign disease?*
- ◆ Epidemiology of other common seasonal respiratory viruses in HSCT during SARS-COV-2 pandemic
- ◆ Fungal and bacterial superinfections in COVID patients
- ◆ Live Q&A

Dina Averbuch (Israel)

José Luis Piñana (Spain)

Carolina Garcia-Vidal (Spain)

19:30-19:40 Break

19:40-20:30 Clinical Impact and management in HSCT patient 4 Chairs: J. Styczynski & R. de la Cámara

Updated in COVID-19 therapy

- ◆ Antivirals, convalescent plasma, immunomodulation
- ◆ Oxygen support, Ventilation, anticoagulation
- ◆ Live Q&A

Malgorzata Mikulska (Italy)
Ellie Azoulay (France)

Thursday, 1 July 2021

**15:00-15:45 Industry Symposium Organised and funded by Jazz Pharmaceuticals
Tackling the challenge of HSCT and hepatic VOD through COVID-19: a case-based approach**

- ◆ Welcome and introduction
- ◆ Paediatric perspective: overcoming the challenges of severe hepatic VOD during the pandemic
- ◆ Adult perspective: overcoming the challenges of severe hepatic VOD during the pandemic
- ◆ Live Q&A, summary and close

Chair: R. Duarte (Spain)
Selim Corbacioglu (Germany)

Rafael Duarte (Spain)

15:45-16:50 Nursing and patients' perspective

- ◆ Nursing HSCT in COVID pandemic
- ◆ PPE and the difficulties of isolation/protective environment
- ◆ Patients' perspective
- ◆ Live Q&A

Chair: J. Murray

Michelle Kenyon (UK)
Iris Agreiter (Ireland)
Natacha Bolaños (Spain)

16:50-17:10 Break

17:10-18:30 Immune response and prevention 1

How is the immune response to SARS-CoV-2?

- ◆ General aspects
How to measure T and B cell response against SARS-COV-2.
Duration of the immune response
Protective immunity: can we define it?
- ◆ Antibody and B cell responses to COVID-19 disease and vaccination
- ◆ Specific aspects of immune response to SARS-CoV-2 in HSCT
- ◆ Live Q&A

Chairs: C. Cordonnier & D. Averbuch

Hans-Gustaf Ljunggren (Sweden)

Karin Loré (Sweden)

Michael Boeck (US)

18:30-18:40 Break

18:40-19:10 Immune response and prevention 2

Vaccines

- ◆ Type of vaccines
- ◆ Experiences in immunosuppressed /HSCT patients
- ◆ Recommendations
- ◆ Live Q&A

Chair: D. Averbuch

Catherine Cordonnier (France)

19:10-19:15 Closing Remarks

Nicolaus Kröger